Varilrix

Varilrix

vaccine, varicella-zoster

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Live attenuated Oka strain of varicella-zoster virus (each dose contains not <103.3 plaque-forming units)
Indications/Uses
Active immunisation against varicella of healthy subjects ≥9 mth, high-risk patients & their susceptible healthy close contacts.
Dosage/Direction for Use
SC Adult & childn ≥9 mth (including high-risk patients) 2 doses. Administer 2nd dose w/ at least 6 wk interval but in no circumstances <4 wk (applicable official recommendations may vary regarding interval between doses & the need for 1 or 2 doses in childn 9 mth-12 yr).
Contraindications
Hypersensitivity to neomycin. Acute severe febrile illness. Primary or acquired immunodeficiency states w/ total lymphocyte count <1,200/mm3 or presenting other evidence of lack of cellular immune competence (eg, leukemia, lymphomas, blood dyscrasias, clinically manifest HIV infection or immunocompromised patients). Pregnancy (during & 3 mth after vaccination).
Special Precautions
Do not administer IV or intradermally.
Adverse Reactions
Pain, redness. Swelling at the inj site; rash, fever.
Drug Interactions
Ig or blood transfusion (delay vaccination for at least 3 mth). Reye's syndrome may occur w/ salicylates. Short-lived suppression of the cell-mediated immune response may occur w/ measles vaccine. Live attenuated vaccines.
ATC Classification
J07BK01 - varicella, live attenuated ; Belongs to the class of varicella viral vaccines.
Presentation/Packing
Form
Varilrix vaccine 0.5 mL
Packing/Price
0.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in